Journal of Viral Hepatitis最新文献

{"title":"Hepatitis A Virus (HAV) Recurrence and De Novo Hepatitis A Acquired at Time of Liver Transplantation: Comparison of Graft HAV Infection and Viral Kinetics","authors":"David Mutimer,&nbsp;Elinor Latham,&nbsp;Sowsan F. Atabani,&nbsp;Samreen Ijaz","doi":"10.1111/jvh.70248","DOIUrl":"https://doi.org/10.1111/jvh.70248","url":null,"abstract":"<p>Hepatitis A virus (HAV) infection is an uncommon indication for liver transplantation, and donor-derived or transfusion-associated HAV infection is rare. Data describing HAV recurrence or early acquisition following liver transplantation, particularly with longitudinal quantitative viral kinetics, are limited. We describe two liver transplant recipients with graft HAV infection occurring in different immunological contexts. One patient underwent emergency liver transplantation for HAV-related acute liver failure and subsequently developed recurrent HAV infection of the graft. The second patient underwent liver transplantation for paracetamol-induced acute liver failure and acquired HAV infection following peri-operative blood transfusion in the early post-transplant period. Serial qualitative and retrospective quantitative HAV ribonucleic acid (RNA) polymerase chain reaction (PCR) measurements were analysed alongside biochemical and clinical parameters. In the patient transplanted for fulminant HAV infection, serum HAV RNA declined rapidly after transplantation, consistent with removal of the infected native liver, followed by recurrent viraemia associated with graft hepatitis during the second and third post-transplant months, and with viral clearance by 4 months. In contrast, the transfusion-acquired HAV infection occurred in the setting of profound immunosuppression and absence of pre-existing immunity, resulting in a higher peak viral load, prolonged viraemia lasting over 9 months, and more severe graft hepatitis. Viral doubling times during viraemic expansion were similar in both cases but sustained high-level viraemia was observed only in the de novo infection. These cases provide novel insights into HAV viral kinetics following liver transplantation and highlight important differences between recurrent infection and newly acquired HAV infection in immunosuppressed recipients.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70248","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timing of Earliest Documented Positive Hepatitis C Laboratory Result Relative to Delivery Among Pregnant Persons With Active Infection in West Virginia, 2022–2023","authors":"Kady Pack,&nbsp;Mamoon Yousaf,&nbsp;Rachel A. Wattick,&nbsp;Brett Armstrong,&nbsp;Birgit Shanholtzer,&nbsp;Tonya Chaney,&nbsp;Shannon McBee,&nbsp;Alana G. Hudson","doi":"10.1111/jvh.70247","DOIUrl":"https://doi.org/10.1111/jvh.70247","url":null,"abstract":"<p>Direct-acting antiviral therapy can cure hepatitis C virus (HCV) infection; however, because treatment is not recommended during pregnancy, preconception treatment remains the primary strategy to prevent perinatal HCV exposure. West Virginia birth records from 2022 to 2023 were linked with statewide HCV laboratory surveillance data. This linked dataset was used to identify births to persons with active HCV infection and characterize the timing of the earliest documented positive HCV laboratory result relative to delivery. A total of 426 deliveries resulting in 433 HCV-exposed live-born infants were identified. Most pregnant persons were aged 25–34 years, White and insured by Medicaid. Overall, 38.5% had their earliest documented positive HCV laboratory result more than 5 years prior to delivery, 36.9% had their first documented positive test 1–5 years prior to delivery and 24.6% had their first documented positive test within 1 year before delivery and up to 2 weeks postpartum. These findings indicate that many pregnant persons with active HCV infection had documented longstanding infection prior to pregnancy, highlighting opportunities to strengthen linkage to care and access to curative treatment before pregnancy.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70247","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Underutilization of Antiviral Therapy and Survival Outcomes in Hepatitis B Virus-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of 78 Studies and 68,243 Patients","authors":"Sahith Kudaravalli,&nbsp;Taotao Yan,&nbsp;Cheng-Hao Tseng,&nbsp;Yao-Chun Hsu,&nbsp;Xiaohe Li,&nbsp;Yuankai Wu,&nbsp;Bowu Chen,&nbsp;Xiangrong Gao,&nbsp;Sicheng Gao,&nbsp;Danfeng Ren,&nbsp;Xiaohan Qian,&nbsp;Warren Sands,&nbsp;Ramsey Cheung,&nbsp;Mindie H. Nguyen","doi":"10.1111/jvh.70245","DOIUrl":"10.1111/jvh.70245","url":null,"abstract":"<div>\u0000 \u0000 <p>Antiviral therapy with nucleos(t)ide analogues is recommended for patients with viremic hepatitis B virus (HBV)-related cirrhosis regardless of levels of viremia or liver enzymes. However, hepatocellular carcinoma (HCC) is not an antiviral treatment criterion in the U.S. HBV treatment guidelines, though prior studies have reported improved survival with antiviral treatment in HBV-related HCC. To inform guidelines, we estimated antiviral treatment rates and their association with survival and HCC recurrence rates in HBV-related HCC. We conducted a systematic review and meta-analysis of studies published between 2006 and 2024 that reported antiviral treatment, survival, and/or HCC recurrence rates in adults with HBV-related HCC, following PRISMA guidelines. Random-effects models pooled study estimates. Of the initial 4556 studies, 178 underwent full-text review, and 78 (68,243 patients) were analysed. The pooled antiviral treatment rate (52 studies, 41,345 patients) was 53.1%. In studies reporting pre-HCC antiviral initiation, 17.2% of HBV-related HCC patients received therapy before diagnosis. Treated (vs untreated) patients had higher 3- and 5-year OS (80.4% vs. 59.2% and 72.1% vs. 46.8%, both <i>p</i> &lt; 0.01). Five-year OS was 78.0% vs. 56.4% in inactive HCC (<i>p</i> &lt; 0.01) and 48.2% vs. 22.6% in active HCC (<i>p</i> = 0.14). Antiviral therapy remained independently associated with improved 5-year OS in multivariable meta-regression. There was no significant difference in HCC recurrence rates. Antiviral therapy is associated with improved long-term survival but remains underutilized in HBV-related HCC. These findings highlight a critical gap in care and underscore the need for earlier and more consistent antiviral initiation in patients with HBV-related HCC.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149182485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New Model of Care Achieving Micro-Elimination of Hepatitis C in the United Kingdom's Largest Prison","authors":"Elizabeth Hurry,&nbsp;Sarah Hulse,&nbsp;Anya Hughes","doi":"10.1111/jvh.70244","DOIUrl":"10.1111/jvh.70244","url":null,"abstract":"<div>\u0000 \u0000 <p>Wales aims to achieve the World Health Organisation goal of eliminating hepatitis C (HCV) as a public health threat by 2030, with micro-elimination in prisons identified as a key target. In January 2022, HMP Berwyn, the largest prison in the United Kingdom, introduced a multi-disciplinary blood borne virus (BBV) team and a streamlined testing and treatment pathway incorporating opt-out testing, peer support, point-of-care viral load testing and pharmacist-led prescribing. This service evaluation describes implementation of the pathway and its outcomes. Data relating to testing and treatment were collected between January 2023 and December 2024. In Welsh prisons micro-elimination of HCV is defined as 100% of the population being offered a test, over 90% accepting testing and over 90% of those testing positive starting treatment. When micro-elimination was first achieved in September 2023, the prison population was 2004. All prisoners had been offered HCV testing in the preceding 12 months and 1915 (95.6%) accepted testing. Twenty-seven men tested HCV PCR positive in the preceding 6 months, and 23 of 24 eligible patients (95.8%) commenced treatment. During 2023 and 2024, 85 men tested HCV PCR positive and 75 of 78 eligible patients (96%) initiated treatment. Median time from diagnosis to treatment initiation was 17 days. Testing uptake remained above 90% during the subsequent 18 months. HMP Berwyn achieved and sustained HCV micro-elimination using a multidisciplinary model that integrated testing and treatment into routine prison healthcare. This model may be transferable to other custodial settings and populations at high-risk of HCV infection.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149167442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Direct-Acting Antiviral Therapy in Patients With Hepatocellular Carcinoma Receiving Non-Curative Treatment: High Sustained Virological Response Rates and Preservation of Liver Functional Reserve","authors":"Shunsuke Sato,&nbsp;Masahiro Yamaguchi,&nbsp;Hiroki Nago,&nbsp;Yoko Kato,&nbsp;Rihwa Om,&nbsp;Yuichiro Terai,&nbsp;Yuji Kita,&nbsp;Yuji Ikeda,&nbsp;Sho Sato,&nbsp;Ayato Murata,&nbsp;Yuji Shimada,&nbsp;Takuya Genda","doi":"10.1111/jvh.70242","DOIUrl":"10.1111/jvh.70242","url":null,"abstract":"<div>\u0000 \u0000 <p>Direct-acting antivirals (DAAs) cure most chronic hepatitis C virus (HCV) infections, but their impact on liver functional reserve in patients with a history of hepatocellular carcinoma (HCC), particularly after non-curative HCC treatment, remains unclear. We evaluated antiviral efficacy and liver functional reserve after DAA therapy according to HCC history and timing of DAA initiation. In this retrospective single-center cohort, 716 patients initiated DAA therapy, and 690 with evaluable sustained virological response at 12 weeks after treatment (SVR12) were analysed. Patients were classified as no HCC, curative-treated HCC, or non-curative-treated HCC according to the most recent HCC treatment before DAA initiation. Liver functional reserve was assessed using the albumin–bilirubin (ALBI) score, modified ALBI grade, and Child–Pugh class. In the non-curative-treated HCC group, early (≤ 3 months) versus delayed (&gt; 3 months) DAA initiation after the most recent HCC treatment was compared. Overall SVR12 was 96.1%, with similarly high rates across groups regardless of HCC history. The median ALBI score improved from −2.35 to −2.58 at SVR12 in the curative-treated HCC group (<i>p</i> &lt; 0.001) but remained unchanged in the non-curative-treated HCC group (−2.36 to −2.38). Among 64 patients with a history of HCC, 43 (67.2%) developed recurrence; in these patients, the ALBI score improved from −2.31 at DAA initiation to −2.57 at recurrence (<i>p</i> &lt; 0.001), and more than 90% remained Child–Pugh class A. Early and delayed DAA initiation showed similarly high SVR12 rates and comparable liver functional reserve. DAAs achieved high SVR12 rates and maintained liver functional reserve in patients with HCV, including those with a history of HCC after non-curative treatment.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149111442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Finite Versus Indefinite Nucleos(t)ide Analogue Therapy in HBeAg‑Negative Chronic Hepatitis B: Meta‑Analysis of Randomized Trials","authors":"Demver P. Gomez,&nbsp;Wilmyr F. Hababag","doi":"10.1111/jvh.70243","DOIUrl":"10.1111/jvh.70243","url":null,"abstract":"<div>\u0000 \u0000 <p>Continuous nucleos(t)ide analogue (NA) therapy for chronic hepatitis B (CHB) effectively maintains viral suppression but rarely results in functional cure. Finite NA therapy has been proposed to increase rates of HBsAg loss; however, international guidelines provide conflicting recommendations. This study compares the efficacy and safety of finite versus continuous NA therapy in HBeAg-negative adults using randomized controlled trials. We included parallel-group randomized controlled trials (RCTs) comparing nucleos(t)ide analogue (NA) cessation versus continuation in non-cirrhotic, virally suppressed HBeAg-negative adults. Two reviewers independently screened studies and assessed risk of bias using Cochrane RoB 2. Random-effects Mantel–Haenszel meta-analyses with Hartung–Knapp adjustment and Paule–Mandel estimation were used to pool risk ratios (RRs) with 95% confidence intervals (CIs). Certainty of evidence was assessed using the GRADE approach. Four RCTs (<i>n</i> = 357) met inclusion criteria. Discontinuation increased HBsAg loss vs. continuation (RR 5.02, 95% CI: 0.47–53.47; <i>I</i>² = 21.8%; low certainty), corresponding to ~53 additional losses per 1000 patients. However, finite therapy markedly increased virologic relapse (RR 23.09) and retreatment (RR 21.94) while reducing sustained off-therapy virologic response (RR 0.46). Post-cessation ALT flares were frequent but self-limited or resolved with retreatment. No hepatic decompensation or serious adverse events occurred. In monitored, non-cirrhotic adults, finite NA therapy may increase the probability of HBsAg loss despite predictable relapse and retreatment. With no evidence of severe harm, these findings support finite therapy as a selective, patient-centered strategy toward functional cure in expert centers.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149111521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Becoming Physically Active and Risks of Mortality and Liver-Related Events in Adults With Chronic Hepatitis B: A Nationwide Cohort Study","authors":"Byeong Geun Song,&nbsp;Myeongcheol Lee,&nbsp;Juhee Cho,&nbsp;Geum-Youn Gwak,&nbsp;Danbee Kang,&nbsp;Dong Hyun Sinn","doi":"10.1111/jvh.70240","DOIUrl":"10.1111/jvh.70240","url":null,"abstract":"<div>\u0000 \u0000 <p>Physical activity (PA) confers several health benefits; however, whether increasing PA among physically inactive adults with chronic hepatitis B (CHB) is associated with lower risks of adverse clinical outcomes remains unclear. We used the nationwide Korean National Health Insurance database. We included 318,131 adults with CHB who were physically inactive at the initial health screening (Exam 1) and completed a subsequent screening within 4 years (Exam 2). Among them, 58,703 initiated moderate-to-vigorous PA (MVPA), defined as vigorous activity ≥ 20 min/day on ≥ 3 days/week or moderate activity ≥ 30 min/day on ≥ 5 days/week. The primary outcome was all-cause mortality, and the secondary outcomes were liver-related events (hepatic decompensation, liver transplantation, hepatocellular carcinoma [HCC]) and HCC. Multivariable Cox and Fine–Grey competing-risk models were adjusted for demographic, clinical, and behavioural factors. During a median 7.9-year follow-up (IQR, 5.2–9.5), 7609 deaths occurred. MVPA initiation was associated with lower all-cause mortality (hazard ratio [HR], 0.89; 95% CI, 0.84–0.94), a lower risk of liver-related events (subdistribution HR [subHR], 0.94; 95% CI, 0.92–0.97), and, more modestly, of HCC (subHR, 0.95; 95% CI, 0.91–0.99) compared with those remaining inactive. The association was more pronounced in older adults, women, never smokers, non-drinkers, and untreated participants (all p for interaction ≤ 0.03). Initiating MVPA among physically inactive adults with CHB was associated with lower risks of mortality and liver-related outcomes. These findings provide large-scale epidemiological evidence supporting further evaluation of PA promotion in physically inactive patients with CHB.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149111439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic Steatosis in People With Chronic Hepatitis B in Africa: Prevalence, Correlates, and Clinical Significance","authors":"Freeman W. Chabala,&nbsp;Edford Sinkala,&nbsp;Alana T. Brennan,&nbsp;Amy Miskimon Goss,&nbsp;Lamin Bojang,&nbsp;Yusupha Samateh,&nbsp;Alexander J. Stockdale,&nbsp;Roger Sombie,&nbsp;Arouna Sessouma,&nbsp;Alice Nanelin Guingane,&nbsp;Juste Aristide Goungounga,&nbsp;Mohamed El-Kassas,&nbsp;Eman Marwan,&nbsp;Ibrahima Diallo,&nbsp;Abdoul Sow,&nbsp;Edith Okeke,&nbsp;Attah Okwute,&nbsp;Hans Prozesky,&nbsp;Zahiera Ismail,&nbsp;Mark Sonderup,&nbsp;C. Wendy Spearman,&nbsp;Philippa C. Matthews,&nbsp;Judicaël Malick Tine,&nbsp;Maud Lemoine,&nbsp;Hailemichael Desalegn Mekonnen,&nbsp;Asgeir Johnannessen,&nbsp;Michael J. Vinikoor,&nbsp;Hepatitis B in Africa Collaborative Network (HEPSANET)","doi":"10.1111/jvh.70241","DOIUrl":"10.1111/jvh.70241","url":null,"abstract":"<p>To address data gaps around metabolic liver disease in Africa, within the Hepatitis B in Africa Collaborative Network (HEPSANET), we evaluated participants with chronic hepatitis B virus infection (CHB) for steatotic liver disease (SLD) using transient elastography with controlled attenuation parameter (CAP). Using multivariable logistic regression, we identified sociodemographic, anthropometric, and clinical associations with SLD (CAP ≥ 248 dB/m), and evaluated whether SLD severity was independently associated with fibrosis. Short-term impacts of SLD on mortality were also assessed with Cox proportional hazards analysis. We also evaluated the diagnostic performance of B-mode ultrasound for SLD, with CAP as reference. Across 6 countries and 1601 participants (age range, 12–80 years; 39.5% female; 4% with diabetes; 11% unhealthy alcohol use; median body mass index, 24.4), 421 (26.3%) had SLD; 219 (13.7%) had severe steatosis (CAP ≥ 280 dB/m). Older age, male sex, overweight and obesity, and HIV-negative status were associated with SLD. After adjusting for age, sex, HIV status, HBV treatment, and country, severe steatosis, but not mild and moderate forms (i.e., 248–279 dB/m), was associated with a 8.4% (95%, 1.9%–14.9%) increased probability of fibrosis. Over limited follow-up (median 2.69 years) and small number of deaths, SLD was not associated with all-cause or liver-related mortality. B-mode ultrasound had low sensitivity for SLD, overall or when severe, but specificity was 95%. In conclusion, SLD was common in people with CHB in Africa and its severe form was associated with liver fibrosis. These data support screening for metabolic comorbidities as part of HBV care and treatment in Africa.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13635601/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149111526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, Regional and National Burden of Viral Hepatitis From 1990 to 2021 With Forecasts to 2046: Findings From the Global Burden of Disease Study 2021","authors":"Jiyuan Ren,&nbsp;Ran Ji,&nbsp;Zimo Zhu,&nbsp;Xinxin Ren,&nbsp;Fanyun Kong,&nbsp;Hongjuan You,&nbsp;Xiaoge Gao,&nbsp;Feitong Wang,&nbsp;Renxian Tang,&nbsp;Xiangye Liu","doi":"10.1111/jvh.70236","DOIUrl":"10.1111/jvh.70236","url":null,"abstract":"<div>\u0000 \u0000 <p>Viral hepatitis constitutes a primary cause of liver cirrhosis and carcinoma and ranks as the second leading cause of mortality worldwide due to challenges in early detection and limited preventive measures, thereby posing a significant threat to public health. This study analyses the burden and risk factors associated with viral hepatitis at global, regional, and national levels from 1990 to 2021, and projects the disease burden from 2022 to 2046. From 1990 to 2021, the global burden of viral hepatitis increased, despite a decline in age-standardized rates. Population growth emerged as the primary driver influencing this trend, with the highest disease burden observed in the African region. A high body-mass index (BMI) demonstrated a distinct and significant association with the sustained increase in disease burden. Excessive alcohol consumption was identified as the leading cause of hepatitis B, while drug abuse was predominantly linked to hepatitis C. Notably, males exhibited a markedly higher susceptibility to these risk factors compared to females. Over the next 25 years, the disease burden of hepatitis A, B, C and E is projected to remain stable or decline. Viral hepatitis remains a significant global public health challenge. It is imperative to strengthen efforts to prevent alcohol and drug abuse, consistently advance disease detection and treatment methods, and enable low- and middle-income countries to improve healthcare infrastructure and expand vaccination coverage. These measures are essential to promptly reduce the disease burden and achieve the goal of eliminating viral hepatitis by 2030.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149111543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can Point-of-Care Ultrasound for Hepatitis (PUSH) Protocol Be Considered an HCC Screening Tool? Methodological Considerations From a Validation Study","authors":"Viji Gunasekaran,&nbsp;Thirunavukkarasu Arun Babu","doi":"10.1111/jvh.70239","DOIUrl":"https://doi.org/10.1111/jvh.70239","url":null,"abstract":"","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149068525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}